Abstract
A series of 47 structurally diverse MGBs, derived from the natural product distamycin, was evaluated for anti-lung cancer activity by screening against the melanoma cancer cell line B16-F10. Five compounds have been found to possess significant activity, more so than a standard therapy, Gemcitabine. Moreover, one compound has been found to have an activity around 70-fold that of Gemcitabine and has a favourable selectivity index of greater than 125. Furthermore, initial studies have revealed this compound to be metabolically stable and thus it represents a lead for further optimisation towards a novel treatment for lung cancer
Information
Library
Documents
MGB Lung Cancer Paper Online Version.pdf
- Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.
Available under License Creative Commons Attribution Non-commercial No Derivatives.
Download (1MB) | Preview
Statistics
Downloads
Downloads per month over past year